Evaluation of clinical events and costs associated with the addition of dapagliflozin to chronic kidney disease treatment: Cost offset analysis

Background and objectives: Chronic kidney disease (CKD) is a serious health problem with an increasing clinical, social and economic impact in advanced stages. Dapagliflozin is a sodium-glucose cotransporter-2 inhibitor that reduces the risk of CKD progression, in addition to provide cardiovascular...

תיאור מלא

מידע ביבליוגרפי

Principais autores:	Juan Francisco Navarro-González, Alberto Ortiz, Ana Cebrián Cuenca, Lluís Segú, Belén Pimentel, Unai Aranda, Blanca Lopez-Chicheri, Margarita Capel, Elisenda Pomares Mallol, Christian Caudron, Juan José García Sánchez, Roberto Alcázar Arroyo
פורמט:	Artigo
שפה:	Inglês
יצא לאור:	Elsevier 2024-11-01
סדרה:	Nefrología (English Edition)
נושאים:	Compensación de costes Dapagliflozina Enfermedad renal crónica Evaluación económica
גישה מקוונת:	http://www.sciencedirect.com/science/article/pii/S2013251424002232
תגים:	הוספת תג אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!